1. Accueil >
  2. Chr. Hansen and Lonza establish a 50/50 joint venture to pioneer the emerging market for live biotherapeutic products >
Nasdaq

Chr. Hansen and Lonza establish a 50/50 joint venture to pioneer the emerging market for live biotherapeutic products

02-04-2019

Company Announcement No. 4/2019

Announcement attached below

For further information, please contact:

Head of Investor Relations
Martin Riise
Tel.: +45 5339 2250 

Investor Relations Officer
Annika Stern
Tel.: +45 2399 2382

Head of Media Relations
Camilla Lercke
Tel.: +45 5339 2384

Attachment